查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445537

Tyrosine kinase抑制劑市場評估：按結合模式、類型、應用、最終用戶和地區劃分的機會和預測（2017-2031）

Tyrosine Kinase Inhibitors Market Assessment, By Mode of Binding, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5個工作天內

價格

全球Tyrosine kinase抑制劑市場規模將從 2023 年的 606 億美元增至 2031 年的 1045.1 億美元，2024-2031 年預測期間複合年增長率為 7.05%，預計將會成長。

過去幾年，Tyrosine kinase抑制劑的藥物發現發生了顯著變化。 新藥和有效方法的引入創造了針對癌細胞的有效且特異性的生長抑制劑，為該行業提供了多種前景。 癌症盛行率增加、研究活動增加以及對Tyrosine kinase抑制劑的投資等因素預計將推動市場成長。

癌症發生率上升是推動市場成長的主要因素。 2022年，中國將新增約482萬癌症患者，其中肺癌是最常見的癌症類型。 同樣，2022年日本將新發現1,019,000例癌症病例，其中結直腸癌、胃癌、肺癌/氣管癌、前列腺癌和乳腺癌是最常見的類型。 癌症的高盛行率增加了對各種用於癌症治療的Tyrosine kinase抑制劑的需求。

政府的大量投資透過對研發活動的支持來提振市場。 政府機構和研究中心之間的合作在開發Tyrosine kinase抑制劑的尖端技術方面取得了重大進展。 例如，根據美國國立衛生研究院2022年5月發布的數據，美國癌症研究支出從2021年的73.62億美元增加到2022年的76.44億美元。

癌症盛行率增加

癌症盛行率的增加預計將顯著促進全球Tyrosine kinase抑制劑市場的擴張。 隨著不同類型癌症的盛行率持續上升，對先進且有效的治療解決方案的需求不斷增長。 Tyrosine kinase抑制劑因其有針對性的作用機制和減少的副作用而在癌症治療方案中獲得認可，使其成為患者和醫療保健專業人員的首選。 針對不同癌症類型的適應症的持續研發是市場成長的驅動因素。

加大Tyrosine kinase抑制劑研發投入

臨床研發正在推動全球Tyrosine kinase抑制劑市場的成長。 越來越多地關注了解癌症生物學和新的治療標靶對市場擴張做出了重大貢獻。 製藥公司和學術機構對研發活動的大力投資進一步推動了市場成長。

技術進步

精準醫學的進步正在推動全球市場的成長，它可以根據個別患者的基因特徵進行個人化治療。 隨著診斷技術和基因分析變得更加先進，我們正在提高識別特定基因變化的能力，並為基因異常提供更個人化和成功的治療計劃。

越來越關注罕見疾病和遺傳性疾病

對罕見疾病和遺傳疾病的關注也推動了全球Tyrosine kinase抑制劑市場的成長。 Tyrosine kinase抑制劑是一種標靶治療方法，因其解決與罕見和遺傳性疾病相關的特定遺傳異常的潛力而受到認可。 隨著精準醫學受到關注，這些疾病獨特的遺傳特徵變得越來越明顯，從而產生了對客製化治療的需求。

本報告調查了全球Tyrosine kinase抑制劑市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。分析、案例研究、競爭格局、以及主要公司的簡介。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球Tyrosine kinase抑制劑市場展望

  • 市場規模/預測
  • 依裝訂樣式
    • I 型抑制劑
    • II 型抑制劑
    • III 型抑制劑
    • IV 型抑制劑
    • V 型抑制劑
  • 依類型
    • 非受體Tyrosine kinase抑制劑
    • 受體Tyrosine kinase抑制劑
    • 多激□抑制劑
    • 絲胺酸/蘇胺酸激□抑制劑
    • 蛋白激□C抑制劑
    • RHO激□抑制劑
    • 其他
  • 依用途
    • 慢性骨髓性白血病 (CML)
    • 肺癌
    • 乳癌
    • 腎細胞癌
    • 其他
  • 按最終用戶
    • 醫院
    • 研究中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球Tyrosine kinase抑制劑市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 依裝訂樣式
  • 依類型
  • 依用途
  • 按最終用戶
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • AbbVie Inc.
  • Astra Zenca PLC
  • Bayer AG
  • Boehringer Ingelheim International Gmbh
  • Abott Inc.
  • Bristol Myers Squibb
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi S A
  • Eisai Co. Ltd

第 13 章策略建議

第 14 章關於我們公司/免責聲明

Product Code: MX11086

Global tyrosine kinase inhibitors market is projected to witness a CAGR of 7.05% during the forecast period 2024-2031, growing from USD 60.6 billion in 2023 to USD 104.51 billion in 2031. Tyrosine kinase inhibitors are regarded as certain enzymes that aid in impeding the growth of malignant cells and the process of cell division as they obstruct the signals that encourage cancer cells to proliferate, these inhibitors are simple to use and helpful in the treatment of cancer patients. Drug discovery for tyrosine kinase inhibitors has changed significantly in the last several years. There have been several prospects for the industry with the introduction of new medications and efficient methods for creating strong and specific growth inhibitors for cancer cells. Factors like the increasing prevalence of cancer, growing research activities, and investment in tyrosine kinase inhibitors are expected to enhance market growth.

The rising incidence of cancer is a major factor driving the market growth. For instance, China experienced approximately 4,820,000 new cancer cases in 2022, with lung cancer being the most common type of cancer. Similarly, in Japan 1,019,000 new cases of cancer were detected in 2022 with colon/rectum cancer, stomach cancer, lung/trachea cancer, prostate cancer, and breast cancer being the most common types. The high incidence of cancers has increased the demand for various tyrosine kinase inhibitor drugs for the treatment of cancers.

Significant investments from the governments have boosted the market through support towards research and development activities. Collaborations between government institutions and research centers have led to significant advancements in developing modern technologies for tyrosine kinase inhibitors. For instance, the amount spent on cancer research in the United States went from USD 7,362 million in 2021 to USD 7,644 million in 2022, according to data released by the NIH in May 2022.

Rising Prevalence of Cancer

The increasing prevalence of cancer is anticipated to significantly boost the expansion of global tyrosine kinase inhibitors market. As the prevalence of various cancer types continues to rise, there is an increasing demand for advanced and effective therapeutic solutions. Tyrosine kinase inhibitors (TKIs) are a crucial class of drugs that have shown remarkable effectiveness in blocking the abnormal activity of tyrosine kinases which are frequently linked to the advancement of cancer. TKIs have gained acceptance in oncology treatment regimens due to their targeted mechanism of action and reduced adverse effects, making them a preferred choice for both patients and healthcare professionals. Ongoing research and development efforts to expand the application of TKIs across diverse cancer indications are driving market growth.

The Indian Council of Medical Research (ICMR) released a bi-annual report in December 2022 that stated the country's average cancer case count for 2022 was 100.4 per 100,000 people, with a high proportion of women (estimated at 105.4 per 100,000) receiving a breast cancer diagnosis. Also, based on data from Cancer Research UK, there were around 17 million new cases of cancer recorded globally in 2018, and by 2040, expected to be over 27.5 million new cases reported globally.

Increasing Investments for Research & Development of TKI

Clinical research and development are driving the growth of global tyrosine kinase inhibitors market due to several factors. The increasing focus on understanding cancer biology and novel therapeutic targets is a significant contributor to the expansion of TKI market. The robust investment in research and development activities by pharmaceutical companies and academic institutions is fostering market growth further.

Clinical trials play a pivotal role in evaluating the safety and efficacy of new TKIs, leading to regulatory approvals and market entry. The continuous exploration of TKIs across diverse cancer indications through well-designed clinical studies enhances their application spectrum and broadens the market's reach. These ongoing trials, confirm the TKI's potential as therapeutics and add to the body of empirical data supporting their clinical usefulness. Furthermore, commercial players, academic institutions, and regulatory agencies are working together to expedite the clinical development process and bring novel TKIs to the markets sooner.

Theseus Pharmaceuticals, Inc., disclosed business and pipeline highlights in August 2022, said to be concentrating on creating next-generation tyrosine kinase inhibitors (TKIs) to develop cancer resistance. Theseus Pharmaceuticals Inc. invested USD 7.3 million in the second quarter of 2022. Therefore, it is anticipated that the market will rise more because of the expanding research efforts and rising investments in tyrosine kinase inhibitors.

Technological Advancements

The advancement of precision medicine is driving the growth of the global tyrosine kinase inhibitors market due to its ability to tailor treatments to individual patients based on their genetic profiles. As diagnostic technologies and genetic profiling become more advanced, the ability to identify specific genetic alterations increases as TKIs are targeted medicines, providing a more individualized and successful treatment plan for genetic defects.

Healthcare practitioners can more accurately match patients to the best TKIs based on their genetic profile due to the growing integration of genomics and molecular diagnostics in cancer care. By specifically targeting cancer cells, it reduces the side effects while still optimizing therapy outcomes. Consequently, the demand for tyrosine kinase inhibitors is expected to increase as precision medicine continues to evolve. Pfizer Inc. was granted approval by the US FDA in March 2021 for a supplemental New Drug Application (sNDA) for the tyrosine kinase inhibitor LORBRENA (lorlatinib), extending its indication to include first-line treatment of patients with non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK). Adults with metastatic NSCLC whose tumors are ALK-positive, as determined by an FDA-approved test, might consider LORBRENA.

Increasing Focus on Rare and Genetic Disorders

The focus on rare and genetic disorders is driving the growth of global tyrosine kinase inhibitors (TKI) market. TKIs, known for their targeted therapeutic approach, are increasingly recognized for their potential to address specific genetic aberrations associated with rare and genetic disorders. As precision medicine gains prominence, the unique genetic signatures of these disorders become more apparent, creating a demand for tailored treatments.

The specificity of TKIs allows for precise targeting of the underlying molecular abnormalities, making them suitable for therapeutic interventions in rare and genetic disorders. Pharmaceutical companies are strategically investing in research and development to explore the applicability of TKIs in these niche markets while driving innovation and expanding the potential use of these inhibitors beyond conventional cancer indications. Moreover, regulatory incentives and orphan drug labels in case of rare diseases create a beneficial environment for market growth.

As healthcare systems and stakeholders increasingly recognize the unmet needs in rare and genetic disorders, the tyrosine kinase inhibitors market is positioned to capitalize on these opportunities, contributing to the advancement of therapeutic options and meeting the specific requirements of patients with these unique conditions. In September 2022, Dizal presented encouraging safety and pharmacokinetic results from the global phase I study of DZD1516 in patients who had relapsed after receiving several prior treatments for HER2 positive metastatic breast cancer (HER2+ MBC). DZD1516 is a HER2 tyrosine kinase inhibitor (TKI) that is intended to be taken orally after being highly selective, powerful, reversible, and fully penetrating the blood-brain barrier (BBB).

North America to Dominate Global TKI Market

North America plays a vital role due to its strong healthcare infrastructure, superior research and development skills, and high cancer prevalence. Tyrosine kinase inhibitors are being developed and commercialized by major pharmaceutical companies, most of which, are situated in North America. For TKIs, North America is dedicated towards innovation and early acceptance of new medicines, and it gives them a responsibility of being the world's most prominent region for oncology.

North America's influential role in research, innovation, and healthcare practices positions it as a key region steering the growth trajectory of global tyrosine kinase inhibitors market. Research centers, academic institutions, and pharmaceutical companies are working together to create an environment that is favorable for clinical trials, which advances the knowledge of TKIs in a variety of cancer types. Moreover, as molecular profiling and genetic testing become standard procedures in cancer care, the increased emphasis on personalized treatment plans and precision medicine in North America will increase demand for TKIs. According to American Cancer Society's data for 2023, about 59,610 new cases of leukemia and 20,380 new instances of acute myeloid leukemia (AML) were reported in the United States. The use of tyrosine kinase inhibitor medication is increasing due to the growing prevalence of cancer cases, which is driving the market in North America.

Future Market Scenario (2024 - 2031F)

As the practice of genetic profiling and molecular diagnosis becomes more popular, the identification of specific gene alterations that cause cancer will become more prevalent, enabling new opportunities for personalized medicine.

Various countries are making significant investments in cutting edge research, clinical trials, and drug discovery contributing to the introduction of new and improved TKIs which in return will help in decreasing the prevalence of lung cancer, breast cancer, chronic myeloid leukemia, and others.

Globally, regulatory bodies from different countries are building frameworks to expedite the development process of inhibitors for oncology. The development of targeted therapies has led to a better understanding of cancer biology, allowing for the identification of more specific drug targets and the development of personalized treatment methods.

Key Players Landscape and Outlook

Leading companies like AbbVie Inc., Astra Zenca PLC, Bayer AG, Boehringer Ingelheim International Gmbh, Abott Inc., Bristol Myers Squibb, Pfizer Inc., Merck & Co., Inc., Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc), F. Hoffmann-La Roche Ltd, Novartis AG, in the kinase inhibitors market have a big influence on the dynamics of the business. These massive pharmaceutical companies are well known for their ongoing commitment towards the development and research of kinase inhibitor. Their impact goes beyond the creation of new products as they actively participate in clinical studies and strategic alliances to increase the use of inhibitors in oncology and other therapeutic areas. These companies are at the forefront of kinase inhibitor therapy innovation and have a significant influence on the market's expansion and future implications for precision medicine and cancer treatment.

The European commission approved the tyrosine kinase inhibitor capmatinib (Tabrecta) in June 2022 as a single treatment for patients with advanced non-small cell lung cancer (NSCLC) with MET exon14 skipping (METex14) altered. These patients need systemic therapy after receiving immunotherapy and/or platinum-based chemotherapy in the past. Merck announced in February 2022 that the European Commission (EC) had authorized once-daily oral TEPMETKO (tepotinib), a tyrosine kinase inhibitor, as a monotherapy for adult patients with advanced non-small cell lung cancer (NSCLC).

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Tyrosine Kinase Inhibitors Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Mode of Binding
    • 4.2.1. Type I Inhibitors
    • 4.2.2. Type II Inhibitors
    • 4.2.3. Type III Inhibitors
    • 4.2.4. Type IV Inhibitors
    • 4.2.5. Type V Inhibitors
  • 4.3. By Type
    • 4.3.1. Non-Receptor Tyrosine Kinase Inhibitors
      • 4.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 4.3.1.2. BCR-ABL
      • 4.3.1.3. Janus Kinase (JAK) Inhibitor
      • 4.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 4.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 4.3.1.6. Others
    • 4.3.2. Receptor Tyrosine Kinase Inhibitors
      • 4.3.2.1. VEGFR
      • 4.3.2.2. PDGFR
      • 4.3.2.3. EGFR
      • 4.3.2.4. ALK
      • 4.3.2.5. HER2
      • 4.3.2.6. Others
    • 4.3.3. Multikinase Inhibitors
    • 4.3.4. Serine/Threonine Kinase Inhibitors
    • 4.3.5. Protein Kinase C Inhibitors
    • 4.3.6. RHO Kinase Inhibitors
    • 4.3.7. Others
  • 4.4. By Application
    • 4.4.1. Chronic Myeloid Leukemia (CML)
    • 4.4.2. Lung Cancer
    • 4.4.3. Breast Cancer
    • 4.4.4. Renal Cell Cancer
    • 4.4.5. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Research Centers
    • 4.5.3. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Tyrosine Kinase Inhibitors Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Mode of Binding
      • 5.1.2.1. Type I Inhibitors
      • 5.1.2.2. Type II Inhibitors
      • 5.1.2.3. Type III Inhibitors
      • 5.1.2.4. Type IV Inhibitors
      • 5.1.2.5. Type V Inhibitors
    • 5.1.3. By Type
      • 5.1.3.1. Non-Receptor Tyrosine Kinase Inhibitors
      • 5.1.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 5.1.3.1.2. BCR-ABL
      • 5.1.3.1.3. Janus Kinase (JAK) Inhibitor
      • 5.1.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 5.1.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 5.1.3.1.6. Others
      • 5.1.3.2. Receptor Tyrosine Kinase Inhibitors
      • 5.1.3.2.1. VEGFR
      • 5.1.3.2.2. PDGFR
      • 5.1.3.2.3. EGFR
      • 5.1.3.2.4. ALK
      • 5.1.3.2.5. HER2
      • 5.1.3.2.6. Others
      • 5.1.3.3. Multikinase Inhibitors
      • 5.1.3.4. Serine/Threonine Kinase Inhibitors
      • 5.1.3.5. Protein Kinase C Inhibitors
      • 5.1.3.6. RHO Kinase Inhibitors
      • 5.1.3.7. Others
    • 5.1.4. By Application
      • 5.1.4.1. Chronic Myeloid Leukemia (CML)
      • 5.1.4.2. Lung Cancer
      • 5.1.4.3. Breast Cancer
      • 5.1.4.4. Renal Cell Cancer
      • 5.1.4.5. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Research Centers
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Mode of Binding
      • 5.1.6.2.1. Type I Inhibitors
      • 5.1.6.2.2. Type II Inhibitors
      • 5.1.6.2.3. Type III Inhibitors
      • 5.1.6.2.4. Type IV Inhibitors
      • 5.1.6.2.5. Type V Inhibitors
      • 5.1.6.3. By Type
      • 5.1.6.3.1. Non-Receptor Tyrosine Kinase Inhibitors
      • 5.1.6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 5.1.6.3.1.2. BCR-ABL
      • 5.1.6.3.1.3. Janus Kinase (JAK) Inhibitor
      • 5.1.6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 5.1.6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 5.1.6.3.1.6. Others
      • 5.1.6.3.2. Receptor Tyrosine Kinase Inhibitors
      • 5.1.6.3.2.1. VEGFR
      • 5.1.6.3.2.2. PDGFR
      • 5.1.6.3.2.3. EGFR
      • 5.1.6.3.2.4. ALK
      • 5.1.6.3.2.5. HER2
      • 5.1.6.3.2.6. Others
      • 5.1.6.3.3. Multikinase Inhibitors
      • 5.1.6.3.4. Serine/Threonine Kinase Inhibitors
      • 5.1.6.3.5. Protein Kinase C Inhibitors
      • 5.1.6.3.6. RHO Kinase Inhibitors
      • 5.1.6.3.7. Others
      • 5.1.6.4. By Application
      • 5.1.6.4.1. Chronic Myeloid Leukemia (CML)
      • 5.1.6.4.2. Lung Cancer
      • 5.1.6.4.3. Breast Cancer
      • 5.1.6.4.4. Renal Cell Cancer
      • 5.1.6.4.5. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Research Centers
      • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Mode of Binding
  • 6.2. By Type
  • 6.3. By Application
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Key Players Landscape

  • 9.1. Competition Matrix of Top Five Market Leaders
  • 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 9.4. SWOT Analysis (For Five Market Players)
  • 9.5. Patent Analysis (If Applicable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

  • 12.1. AbbVie Inc.
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products & Services
    • 12.1.4. Financials (As reported)
    • 12.1.5. Key Market Focus & Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Astra Zenca PLC
  • 12.3. Bayer AG
  • 12.4. Boehringer Ingelheim International Gmbh
  • 12.5. Abott Inc.
  • 12.6. Bristol Myers Squibb
  • 12.7. Pfizer Inc.
  • 12.8. Merck & Co., Inc.
  • 12.9. Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
  • 12.10. F. Hoffmann-La Roche Ltd
  • 12.11. Novartis AG
  • 12.12. Sanofi S A
  • 12.13. Eisai Co. Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 4. Global Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 5. Global Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 6. Global Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Tyrosine Kinase Inhibitors Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10. North America Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 11. North America Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 12. North America Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17. United States Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 18. United States Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 19. United States Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 20. United States Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23. Canada Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 24. Canada Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 25. Canada Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 26. Canada Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 30. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 31. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 32. Mexico Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35. Europe Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 36. Europe Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 37. Europe Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 38. Europe Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42. Germany Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 43. Germany Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 44. Germany Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 45. Germany Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. France Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 49. France Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 50. France Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 51. France Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54. Italy Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 55. Italy Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 56. Italy Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 57. Italy Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 61. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 62. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 63. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66. Russia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 67. Russia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 68. Russia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 69. Russia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 73. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 74. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 75. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78. Spain Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 79. Spain Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 80. Spain Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 81. Spain Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 85. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 86. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 87. Turkey Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Poland Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 91. Poland Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 92. Poland Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 93. Poland Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96. South America Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 97. South America Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 98. South America Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 99. South America Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 104. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 105. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 106. Brazil Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 110. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 111. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 112. Argentina Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 116. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 117. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 118. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 120. India Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122. India Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 123. India Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 124. India Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 125. India Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128. China Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 129. China Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 130. China Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 131. China Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134. Japan Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 135. Japan Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 136. Japan Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 137. Japan Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140. Australia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 141. Australia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 142. Australia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 143. Australia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 147. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 148. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 149. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 153. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 154. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 155. South Korea Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 159. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 160. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 161. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 165. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 166. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 167. Philippines Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 171. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 172. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 173. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 178. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 179. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 180. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. UAE Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 184. UAE Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 185. UAE Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 186. UAE Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
  • Figure 190. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
  • Figure 191. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 192. South Africa Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Mode of Binding Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023